Nkarta Posts $40.4M Q2 Loss, Cash Runway Into 2029; Key Trial Data Expected This Year
NKTX sits 39% above its 52-week low of $1.7.
Summary
Nkarta reported a Q2 net loss of $40.4 million, or $0.54 per share, with $243.2 million in cash and investments, which the company expects to fund its current operating plan into 2029. Enrollment continues in the Ntrust-1 and Ntrust-2 trials at the 4 billion cell dose level, with initial clinical data expected later this year. The company also began outpatient dosing of NKX019 at community sites, broadening access, and is evaluating the therapy as a single agent without supplemental cytokines. The cash runway provides a long buffer, but the near-term catalyst is the upcoming data readout, which will be critical for validating the platform.
At the time of this announcement, NKTX was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $176M. The 52-week trading range was $1.70 to $3.72. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.